{"id":"idrocilamide","rwe":[{"pmid":"32022481","year":"2020","title":"New Efficient Eco-Friendly Supported Catalysts for the Synthesis of Amides with Antioxidant and Anti-Inflammatory Properties.","finding":"","journal":"ChemMedChem","studyType":"Clinical Study"},{"pmid":"10976659","year":"2000","title":"Clinically significant pharmacokinetic interactions between dietary caffeine and medications.","finding":"","journal":"Clinical pharmacokinetics","studyType":"Clinical Study"},{"pmid":"7583181","year":"1995","title":"Therapeutic trials in digital osteoarthritis. A critical review.","finding":"","journal":"Revue du rhumatisme (English ed.)","studyType":"Clinical Study"},{"pmid":"8180884","year":"1993","title":"Two sites of action for LCB29 (idrocilamide) in depressing mechanical tension of rat soleus muscle fibers?","finding":"","journal":"Canadian journal of physiology and pharmacology","studyType":"Clinical Study"},{"pmid":"8012322","year":"1993","title":"[Tissue and systemic diffusion of idrocilamide after cutaneous administration].","finding":"","journal":"Revue du rhumatisme (Ed. francaise : 1993)","studyType":"Clinical Study"}],"tags":[{"label":"idrocilamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"M02AX05","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"srilane","offLabel":[],"synonyms":["idrocilamide","brolitene","srilane"],"timeline":[],"approvals":[],"brandName":"Srilane","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"idrocilamide","explanation":"Think of it like a leaky faucet - carbonic anhydrase helps regulate the amount of acid in the body. When it's working properly, it helps keep the body's pH levels in balance. Idrocilamide may help by blocking this enzyme, which can help reduce the amount of acid in the body.","oneSentence":"Idrocilamide is thought to work by inhibiting the enzyme carbonic anhydrase, which plays a role in maintaining acid-base balance in the body.","technicalDetail":"Idrocilamide is a reversible, non-competitive inhibitor of carbonic anhydrase, which is involved in the regulation of acid-base balance through the reversible hydration of carbon dioxide to bicarbonate and protons."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Idrocilamide","title":"Idrocilamide","extract":"Idrocilamide is a medication with skeletal muscle relaxant and anti-inflammatory actions used as a topical cream to treat lumbago and other kinds of muscular pain. It is available on prescription or over-the-counter in France and various other countries."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1418","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IDROCILAMIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Idrocilamide","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T13:55:23.822809","biosimilars":[],"competitors":[{"drugName":"tolazoline","drugSlug":"tolazoline","fdaApproval":"1948-03-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"dimethyl sulfoxide","drugSlug":"dimethyl-sulfoxide","fdaApproval":"1978-04-04","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"idrocilamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"tolazoline","brandName":"tolazoline","genericName":"tolazoline","approvalYear":"1948","relationship":"same-class"},{"drugId":"dimethyl-sulfoxide","brandName":"dimethyl sulfoxide","genericName":"dimethyl sulfoxide","approvalYear":"1978","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005257","UNII":"6C816LUB1O","CHEBI":"CHEBI:134842","INN_ID":"3547","RXNORM":"19729","UMLSCUI":"C0054086","ChEMBL_ID":"CHEMBL102358","KEGG_DRUG":"D08063","DRUGBANK_ID":"DB13297","PUBCHEM_CID":"1550874","SNOMEDCT_US":"16311000122105","MESH_SUPPLEMENTAL_RECORD_UI":"C004560"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.35 hours","clearance":"0.99 mL/min/kg","volumeOfDistribution":"0.11 L/kg"},"publicationCount":14,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"M02AX05","allCodes":["M02AX05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2020 Mar 5","pmid":"32022481","title":"New Efficient Eco-Friendly Supported Catalysts for the Synthesis of Amides with Antioxidant and Anti-Inflammatory Properties.","journal":"ChemMedChem"},{"date":"2000 Aug","pmid":"10976659","title":"Clinically significant pharmacokinetic interactions between dietary caffeine and medications.","journal":"Clinical pharmacokinetics"},{"date":"1995 Jun","pmid":"7583181","title":"Therapeutic trials in digital osteoarthritis. A critical review.","journal":"Revue du rhumatisme (English ed.)"},{"date":"1993 Dec","pmid":"8180884","title":"Two sites of action for LCB29 (idrocilamide) in depressing mechanical tension of rat soleus muscle fibers?","journal":"Canadian journal of physiology and pharmacology"},{"date":"1993 Dec","pmid":"8012322","title":"[Tissue and systemic diffusion of idrocilamide after cutaneous administration].","journal":"Revue du rhumatisme (Ed. francaise : 1993)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Idrocilamide is a small molecule drug in the idrocilamide class, but its target and approved indications are unknown. Its commercial status is unclear, and it is not known if it is patented or available as a generic. The half-life of idrocilamide is approximately 1.35 hours, but its bioavailability and off-patent status are unknown. As a result, there is limited information available about this compound. Further research is needed to determine its clinical utility and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}